<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50333">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01980329</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00078492</org_study_id>
    <nct_id>NCT01980329</nct_id>
  </id_info>
  <brief_title>Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites</brief_title>
  <official_title>Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the influence of genetic polymorphism of cytochrome
      P450 3A5 on pharmacokinetics of maraviroc and its oxidative metabolites
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate the effects of CYP3A5 genotype on pharmacokinetics of maraviroc
      and its oxidative metabolites. A single oral dose of 300 mg maraviroc will be given to 24
      eligible healthy individuals who will be screened and determined to have specific CYP3A5
      genotype - 8 homozygous wild type (2 CYP3A5*1 alleles), 8 heterozygous (1 CYP3A5*1 allele
      and 1 mutant allele), and 8 without wild type genotype (2 mutant alleles). Blood samples
      will be drawn and urine samples will be collected immediately before and during a 32-hr
      period following the dose. The concentrations of maraviroc and its oxidative metabolites
      from the blood and urine samples will be measured and the pharmacokinetics of maraviroc and
      its metabolites will be compared among the three groups with different CYP3A5 polymorphic
      status.

      --------------------------------------------------------------------------------
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve</measure>
    <time_frame>0-32 hour post dose administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>0-32 hr post dose administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma peak concentration</measure>
    <time_frame>0-32 hr post dose administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life</measure>
    <time_frame>0-32 hr post dose administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary metabolic ratio</measure>
    <time_frame>0-32 hr post dose administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Cytochrome P450 CYP3A5 Enzyme Polymorphism</condition>
  <condition>Healthy Subjects</condition>
  <condition>Pharmacokinetics of Maraviroc</condition>
  <arm_group>
    <arm_group_label>Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral administration of 300 mg maraviroc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <arm_group_label>Maraviroc</arm_group_label>
    <other_name>Selzentry</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy with no acute medical illness

          -  Willing to provide written informed consent

          -  Age 18-65 years

          -  Negative serum pregnancy test (females only) at screening and a negative      urine
             pregnancy test (females only) on day of dosing

          -  HIV seronegative  at screening, as determined by any licensed ELISA

          -  At screening, no evidence of hepatic or renal impairment (LFT's &lt; 1.5 Upper Limit of
             Normal (ULN), creatinine clearance &gt; than 60 ml/min, total bilirubin below ULN, AST
             and ALT below 1.5 ULN)

          -  8 subjects with homozygous CYP3A5 allele *1 (wild type)

          -  8 subjects with 1 CYP3A5*1 allele and 1 mutant allele

          -  8 subjects with CYP3A5 allele other than *1

        Exclusion Criteria:

          -  Concomitant medication (prescription or over-the-counter) or herbal supplements for
             which there is a known risk of pharmacokinetic or pharmacodynamic drug interactions,
             including those that inhibit CYP3A4 as listed on the P450 Drug Interaction Table
             (http://medicine.iupui.edu/clinpharm/ddis/table.aspx)

          -  History of postural hypotension or cardiovascular disease

          -  Active medical or psychological condition that, in the opinion of the investigator,
             might put the volunteer at undue risk or interfere with the participation of the
             study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Namandje N Bumpus, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig W Hendrix, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Johns Hopkins University School of Medicine Division of Clinical Pharmacology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Namandj√© N. Bumpus, PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>CYP3A5</keyword>
  <keyword>maraviroc</keyword>
  <keyword>polymorphism</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
